These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26733830)

  • 1. To Act or Not to Act: Endocannabinoid/Dopamine Interactions in Decision-Making.
    Hernandez G; Cheer JF
    Front Behav Neurosci; 2015; 9():336. PubMed ID: 26733830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoid Signaling in Motivation, Reward, and Addiction: Influences on Mesocorticolimbic Dopamine Function.
    Sagheddu C; Muntoni AL; Pistis M; Melis M
    Int Rev Neurobiol; 2015; 125():257-302. PubMed ID: 26638769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.
    van der Stelt M; Di Marzo V
    Eur J Pharmacol; 2003 Nov; 480(1-3):133-50. PubMed ID: 14623357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.
    Lupica CR; Riegel AC
    Neuropharmacology; 2005 Jun; 48(8):1105-16. PubMed ID: 15878779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocannabinoid modulation of homeostatic and non-homeostatic feeding circuits.
    Lau BK; Cota D; Cristino L; Borgland SL
    Neuropharmacology; 2017 Sep; 124():38-51. PubMed ID: 28579186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anabolic-androgenic steroids and decision making: Probability and effort discounting in male rats.
    Wallin KG; Alves JM; Wood RI
    Psychoneuroendocrinology; 2015 Jul; 57():84-92. PubMed ID: 25900595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aversive stimuli and loss in the mesocorticolimbic dopamine system.
    Brooks AM; Berns GS
    Trends Cogn Sci; 2013 Jun; 17(6):281-6. PubMed ID: 23623264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions.
    Zlebnik NE; Cheer JF
    J Neurosci; 2016 Oct; 36(40):10230-10238. PubMed ID: 27707960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prenatal Ethanol Exposure Persistently Alters Endocannabinoid Signaling and Endocannabinoid-Mediated Excitatory Synaptic Plasticity in Ventral Tegmental Area Dopamine Neurons.
    Hausknecht K; Shen YL; Wang RX; Haj-Dahmane S; Shen RY
    J Neurosci; 2017 Jun; 37(24):5798-5808. PubMed ID: 28476947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stress induced risk-aversion is reverted by D2/D3 agonist in the rat.
    Morgado P; Marques F; Ribeiro B; Leite-Almeida H; Pêgo JM; Rodrigues AJ; Dalla C; Kokras N; Sousa N; Cerqueira JJ
    Eur Neuropsychopharmacol; 2015 Oct; 25(10):1744-52. PubMed ID: 26233608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic circuitry and risk/reward decision making: implications for schizophrenia.
    Stopper CM; Floresco SB
    Schizophr Bull; 2015 Jan; 41(1):9-14. PubMed ID: 25406370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal dopamine D2 receptors regulate effort but not value-based decision making and alter the dopaminergic encoding of cost.
    Filla I; Bailey MR; Schipani E; Winiger V; Mezias C; Balsam PD; Simpson EH
    Neuropsychopharmacology; 2018 Oct; 43(11):2180-2189. PubMed ID: 30082890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D3 Receptor Availability Is Associated with Inflexible Decision Making.
    Groman SM; Smith NJ; Petrullli JR; Massi B; Chen L; Ropchan J; Huang Y; Lee D; Morris ED; Taylor JR
    J Neurosci; 2016 Jun; 36(25):6732-41. PubMed ID: 27335404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The alcoholic brain: neural bases of impaired reward-based decision-making in alcohol use disorders.
    Galandra C; Basso G; Cappa S; Canessa N
    Neurol Sci; 2018 Mar; 39(3):423-435. PubMed ID: 29188399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoid signaling system and brain reward: emphasis on dopamine.
    Gardner EL
    Pharmacol Biochem Behav; 2005 Jun; 81(2):263-84. PubMed ID: 15936806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The endocannabinoid 2-arachidonoylglycerol inhibits long-term potentiation of glutamatergic synapses onto ventral tegmental area dopamine neurons in mice.
    Kortleven C; Fasano C; Thibault D; Lacaille JC; Trudeau LE
    Eur J Neurosci; 2011 May; 33(10):1751-60. PubMed ID: 21410793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocannabinoid-mediated control of synaptic transmission.
    Kano M; Ohno-Shosaku T; Hashimotodani Y; Uchigashima M; Watanabe M
    Physiol Rev; 2009 Jan; 89(1):309-80. PubMed ID: 19126760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptors antagonistically regulate behavioral choice between conflicting alternatives in C. elegans.
    Wang D; Yu Y; Li Y; Wang Y; Wang D
    PLoS One; 2014; 9(12):e115985. PubMed ID: 25536037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine restores cognitive motivation in Parkinson's disease.
    McGuigan S; Zhou SH; Brosnan MB; Thyagarajan D; Bellgrove MA; Chong TT
    Brain; 2019 Mar; 142(3):719-732. PubMed ID: 30689734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in chloride gradients allow for three distinct types of synaptic modulation by endocannabinoids.
    Wang Y; Burrell BD
    J Neurophysiol; 2016 Aug; 116(2):619-28. PubMed ID: 27226449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.